AI-Designed Vaccine Enters Human Trial Stage

Representational Image.

Researchers have launched human trials of what is being described as the world’s first vaccine designed using artificial intelligence, a development scientists believe could help protect against a wide range of viruses and strengthen preparedness for future pandemics.

Scientists at the University of Cambridge said the vaccine marks the first time an AI-designed core vaccine component has been tested on human volunteers.

The vaccine is designed to target the broader coronavirus family, including current Covid-19 variants as well as related viruses circulating in animals that could potentially trigger future outbreaks.

Although the research remains in its early stages, scientists are already using the same technology to develop vaccines for influenza and Ebola.

Vaccines work by training the immune system to recognise and fight infections. However, many viruses constantly mutate, reducing the effectiveness of existing vaccines over time. This is why Covid-19 and seasonal flu vaccines often require regular updates.

Professor Jonathan Heeney of the University of Cambridge said traditional vaccine development often struggles to keep pace with rapidly evolving viruses. The new approach aims to stay ahead by building immunity not only against existing strains but also against viruses that may emerge in the future.

To develop the vaccine, researchers analysed genetic data from multiple coronaviruses identified through surveillance programmes tracking potential viral threats.

An AI system processed the genetic information and designed what researchers describe as a “super-antigen” — a vaccine component intended to help the immune system recognise and defend against a broad range of related viruses, including those capable of mutating or spreading from animals to humans.

Antigens are essential vaccine components because they trigger immune responses that help the body fight infections.

According to Professor Heeney, this is the first human trial of an AI-designed antigen, a technology he described as highly promising.

“This is about creating vaccines that protect us not only from today’s viruses, but also from those that could cause the next outbreak,” he said.

The initial safety trial involved 39 participants. A larger study involving around 200 people is now underway to assess how effectively the vaccine stimulates immune responses.

Early findings published in the Journal of Infection showed a modest immune response, although researchers remain optimistic about the vaccine’s long-term potential.

Professor Saul Faust of the University of Southampton said the AI-designed vaccine approach could prove especially useful against rapidly evolving viruses with pandemic potential.

Researchers are also testing universal flu vaccines in animals, aiming to reduce the need for yearly reformulations. Work is additionally underway on a vaccine for H5N1 bird flu in case it develops into a human pandemic.

Another area of research includes vaccines for viral haemorrhagic fevers such as Ebola, particularly as outbreaks continue in regions where approved vaccines remain limited.

Professor Andy Pollard, director of the Oxford Vaccine Group, said the approach has already shown promising results in animal studies, though he stressed that human trial outcomes will be the key test.

Experts say artificial intelligence could significantly transform vaccine development by improving predictions of immune responses, speeding up research, and helping save lives.

Professor Marian Knight described the successful testing of the AI-designed “super-antigen” as a major milestone that could lead to broader and longer-lasting protection against infectious diseases.